Inhibition of c-kit in Late Cirrhosis may Restore TGF-β Inhibitory Effect on Somatic Liver Stem Cells and Prevent Development of Hepatocellular Carcinoma (original) (raw)
Related papers
Expression of stem cell factor receptor c-kit in human nontumoral and tumoral hepatic cells
European Journal of Gastroenterology & Hepatology, 2009
Conclusion Hepatocytes express the c-kit receptor at different grade of intensity under normal and altered pathological conditions. The presence of c-kit on HCC cell lines supports the assumption that SCF might play a role in the regulation of proliferative activity of tumorous and nontumorous hepatic cells.
A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer
Neoplasia (New York, N.Y.), 2016
Hepatocellular carcinoma (HCC) is globally the second most common cause of cancer mortality. The majority of HCC patients are diagnosed at advanced stage disease for which no curative treatments exist. TGF-β has been identified as a potential therapeutic target. However, the molecular mechanisms mediating its functional switch from a tumor suppressor to tumor promoter in HCC and its interactions with other signaling pathways are poorly understood. Here, we demonstrate an aberrant molecular network between the TGF-β and c-KIT pathway that mediates the functional switch of TGF-β to a driver of tumor progression in HCC. TGF-β/SMAD2 signaling transcriptionally regulates expression of the c-KIT receptor ligand (stem cell factor [SCF]) with subsequent auto- and paracrine activation of c-KIT/JAK1/STAT3 signaling. SCF induces TGF-β1 ligand expression via STAT3, thereby forming a positive feedback loop between TGF-β/SMAD and SCF/c-KIT signaling. This network neutralizes TGF-β-mediated cell c...
Biochemistry (Moscow), 2019
Liver is the major metabolic, endocrine, exocrine, and defense organ in the body. It consists of several cell types, mainly hepatocytes and cholangiocytes. Other cell types include sinusoidal endothelial, Kupffer, and stellate cells [1]. Hepatocellular carcinoma (HCC) is the major histological subtype among primary liver cancers and accounts for ~80% liver cancers. It has a poor prognosis with the overall five year mortality rate of >88% and rep resents the second most common cause of cancer related deaths worldwide [2]. Recent studies support the cancer stem cell (CSC) hypothesis that claims CSCs as the cause of hepatocar cinogenesis. Over 40% HCCs are considered to be clonal
Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma
Nature Reviews Gastroenterology & Hepatology, 2012
| Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers worldwide. It arises from modulation of multiple genes by mutations, epigenetic regulation, noncoding RNAs and translational modifications of encoded proteins. Although >40% of HCCs are clonal and thought to arise from cancer stem cells (CSCs), the precise identification and mechanisms of CSC formation remain poorly understood. A functional role of transforming growth factor (TGF)-β signalling in liver and intestinal stem cell niches has been demonstrated through mouse genetics. These studies demonstrate that loss of TGF-β signalling yields a phenotype similar to a human CSC disorder, Beckwith-Wiedemann syndrome. Insights into this powerful pathway will be vital for developing new therapeutics in cancer. Current clinical approaches are aimed at establishing novel cancer drugs that target activated pathways when the TGF-β tumour suppressor pathway is lost, and TGF-β itself could potentially be targeted in metastases. Studies delineating key functional pathways in HCC and CSC formation could be important in preventing this disease and could lead to simple treatment strategies; for example, use of vitamin D might be effective when the TGF-β pathway is lost or when wnt signalling is activated.
Hepatology, 1999
The stem cell factor (SCF)/c-kit ligand/receptor system has been implicated in stem (oval) cell activation following liver injury in the rat. The aim of this study was to determine the role of the SCF/c-kit system in pediatric human liver during acute and chronic liver injury. Tissue was obtained from hepatectomy specimens of patients undergoing liver transplantation for extrahepatic biliary atresia (EHBA) and fulminant hepatic failure (FHF). Specific expression of mRNA for c-kit and -actin was measured by ribonuclease protection and by immunohistochemistry to localize c-kit in tissue sections. Expression of c-kit was detected at relatively consistent levels in normal and cirrhotic (EHBA) livers. However, in FHF, c-kit mRNA levels were elevated in 3 of 6 specimens. Immunolocalization highlighted the presence of small numbers of c-kit-positive cells in the portal tracts of normal livers with increased numbers in cirrhotic livers. The highest c-kit staining, however, was observed in FHF, in which, in addition to the cells in the portal tracts, discrete c-kit-positive cells were also found integrated into bile ducts. Colocalization studies demonstrated some of the c-kit-positive cells to be of mast cell, leukocyte, and hematopoietic cell origin. However, there remained a subset that was also negative for these markers. The up-regulation of c-kit receptor expression in diseased livers suggests an involvement of this receptor/ ligand system in hepatic repair mechanisms, and we speculate that c-kit-positive cells may represent a hepatic progenitor cell population. The origin and growth/differentiation potential of these c-kit-positive cells is under investigation. (HEPATOLOGY 1999;30:112-117.) Abbreviations: AAF, 2-acetylaminofluorene; SCF, stem cell factor; EHBA, extrahepatic biliary atresia; FHF, fulminant hepatic failure;
Transforming growth factor‐β in liver cancer stem cells and regeneration
Hepatology Communications, 2017
Cancer stem cells have established mechanisms that contribute to tumor heterogeneity as well as resistance to therapy. Over 40% of hepatocellular carcinomas (HCCs) are considered to be clonal and arise from a stem‐like/cancer stem cell. Moreover, HCC is the second leading cause of cancer death worldwide, and an improved understanding of cancer stem cells and targeting these in this cancer are urgently needed. Multiple studies have revealed etiological patterns and multiple genes/pathways signifying initiation and progression of HCC; however, unlike the transforming growth factor β (TGF‐β) pathway, loss of p53 and/or activation of β‐catenin do not spontaneously drive HCC in animal models. Despite many advances in cancer genetics that include identifying the dominant role of TGF‐β signaling in gastrointestinal cancers, we have not reached an integrated view of genetic mutations, copy number changes, driver pathways, and animal models that support effective targeted therapies for these...
The Rationale for Targeting TGF-β in Chronic Liver Diseases
European journal of clinical investigation, 2016
Transforming growth factor (TGF)-β is a pluripotent cytokine that displays several tissue-specific biological activities. In the liver, TGF-β is considered a fundamental molecule, controlling organ size and growth by limiting hepatocyte proliferation. It is involved in fibrogenesis and therefore in worsening liver damage, as well as in triggering the development of hepatocellular carcinoma (HCC). TGF-β is known to act as an oncosuppressor and also as a tumor promoter in HCC, but its role is still unclear. In this review we discuss the potential role of TGF-β in regulating the tumoral progression of HCC, and therefore the rationale for targeting this molecule in patients with HCC RESULTS: A considerable amount of experimental preclinical evidence suggests that TGF-β is a promising druggable target in patients with HCC. To support this hypothesis, a phase II clinical trial is currently ongoing using a TGF-β pathway inhibitor, and results will soon be available CONCLUSIONS: The identif...
Blocking SCF/c-Kit signal did not inhibit the proliferation of cultured liver progenitor cells
IUBMB Life, 2007
Oval cells are the putative liver stem cells that proliferate during hepatocarcinogenesis and chemically-induced severe liver injury. Antigens traditionally associated with haematopoietic cells, such as c-Kit, have been reported to be expressed by oval cells. Previous studies suggested that stem cell factor (SCF) and c-Kit were critical to oval cell development. However, the role of SCF/c-Kit signals in oval cell proliferation still remains unclear. Recently, we reported the establishment of oval cell-derived liver epithelial progenitor cells (LEPCs). In this work, we showed LEPCs co-expressed c-Kit and its ligand SCF. The involvement of SCF/c-Kit signals in LEPCs proliferation was investigated either by exposing LEPCs to c-Kit inhibitors (STI571 and AG1296), SCF, anti-SCF neutralized antibody or by using small interfering RNA to knock-down c-Kit expression. Our data demonstrate that blocking SCF/c-Kit signal did not inhibit the proliferation of LEPCs, which suggest SCF/c-Kit is not necessary for the proliferation of oval cells, at least for the cultured oval cell counterpart LEPCs.
Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis
Frontiers in Oncology, 2018
The Transforming Growth Factor-beta (TGF-β) family plays relevant roles in the regulation of different cellular processes that are essential for tissue and organ homeostasis. In the case of the liver, TGF-β signaling participates in different stages of disease progression, from initial liver injury toward fibrosis, cirrhosis and cancer. When a chronic injury takes place, mobilization of lymphocytes and other inflammatory cells occur, thus setting the stage for persistence of an inflammatory response. Macrophages produce profibrotic mediators, among them, TGF-β, which is responsible for activation-transdifferentiationof quiescent hepatic stellate cells (HSC) to a myofibroblast (MFB) phenotype. MFBs are the principal source of extracellular matrix protein (ECM) accumulation and prominent mediators of fibrogenesis. TGF-β also mediates an epithelial-mesenchymal transition (EMT) process in hepatocytes that may contribute, directly or indirectly, to increase the MFB population. In hepatocarcinogenesis, TGF-β plays a dual role, behaving as a suppressor factor at early stages, but contributing to later tumor progression, once cells escape from its cytostatic effects. As part of its potential pro-tumorigenic actions, TGF-β induces EMT in liver tumor cells, which increases its pro-migratory and invasive potential. In parallel, TGF-β also induces changes in tumor cell plasticity, conferring properties of a migratory tumor initiating cell (TIC). The main aim of this review is to shed light about the pleiotropic actions of TGF-β that explain its effects on the different liver cell populations. The cross-talk with other signaling pathways that contribute to TGF-β effects, in particular the Epidermal Growth Factor Receptor (EGFR), will be presented. Finally, we will discuss the rationale for targeting the TGF-β pathway in liver pathologies.
Stem cells in liver regeneration, fibrosis and cancer: the good, the bad and the ugly
The Journal of Pathology, 2009
The worldwide shortage of donor livers to transplant end stage liver disease patients has prompted the search for alternative cell therapies for intractable liver diseases, such as acute liver failure, cirrhosis and hepatocellular carcinoma (HCC). Under normal circumstances the liver undergoes a low rate of hepatocyte 'wear and tear' renewal, but can mount a brisk regenerative response to the acute loss of two-thirds or more of the parenchymal mass. A body of evidence favours placement of a stem cell niche in the periportal regions, although the identity of such stem cells in rodents and man is far from clear. In animal models of liver disease, adopting strategies to provide a selective advantage for transplanted hepatocytes has proved highly effective in repopulating recipient livers, but the poor success of today's hepatocyte transplants can be attributed to the lack of a clinically applicable procedure to force a similar repopulation of the human liver. The activation of bipotential hepatic progenitor cells (HPCs) is clearly vital for survival in many cases of acute liver failure, and the signals that promote such reactions are being elucidated. Bone marrow cells (BMCs) make, at best, a trivial contribution to hepatocyte replacement after damage, but other BMCs contribute to the hepatic collagen-producing cell population, resulting in fibrotic disease; paradoxically, BMC transplantation may help alleviate established fibrotic disease. HCC may have its origins in either hepatocytes or HPCs, and HCCs, like other solid tumours appear to be sustained by a minority population of cancer stem cells.